The objectives of the Center for Studies of Host Response to Cancer Therapy are to (1) form a self- sustaining multidisciplinary research center within the University of Arkansas for Medical Sciences (UAMS) that examines mechanisms of and prevention strategies for cancer-therapy-induced toxicity and (2) help junior investigators with a common research focus establish themselves as independent scientists. Achieving these goals will create a vibrant, synergistic research environment to comprehensively address the mechanisms of side effects of cancer therapy and to develop effective strategies to prevent such side effects. To our knowledge, few centers exist that focus on cancer survivors, and none take the paradigm-shifting approach of proactively addressing treatment-related toxicities. Specifically, this Center will provide an environment for young investigators to succeed as independent scientists (Aim 1); strengthen the overall research infrastructure at UAMS and the Cancer Institute (Aim 2); and ensure that the Center for Studies of Host Response to Cancer Therapy becomes self-sustaining (Aim 3). The four initial Project Leaders are promising new/early-stage investigators with their own active research programs and established collaborations with fellow Project Leaders and/or mentors. All are in the tenure track with their own research laboratories, and all have been provided generous institutional startup packages by their departments. Opportunities will be provided by implementing individualized mentoring and faculty development plans and by offering guidance and support from an administrative and two scientific cores. A high likelihood of success is ensured by strong institutional support combined with active interest from funding agencies in improving quality of life among cancer survivors. To replace Project Leaders who achieve independence and graduate from COBRE support, a pipeline of new Project Leaders is ensured through institutional support for recruitment of junior faculty, combined with a structured pilot project program. Building strong Center cores and collaborations with existing institutional cores will also contribute to establishing the Center for Studies of Host Response to Cancer Therapy as a self-sustaining center on campus. The Center's progress will be guided by External and Internal Advisory Committees and a Core Oversight Committee. The Internal Advisory Committee, comprised of individuals in key positions, with broad representation from across the institution and with a vested interest in the Center's achievements, will ensure the initial success of the Center as well as its long-term viability as an independent unit on campus.

Public Health Relevance

Many cancer survivors cured of their original malignancy suffer from treatment-related problems, ranging from mild psychosocial disabilities to life-threatening physical sequelae. Comparatively little effort has been directed toward determining the mechanisms that are responsible for side effects that persist after cancer therapy and at developing effective interventions to prevent them. This COBRE Center addresses these unmet needs and ensures that advances in oncology go hand in hand with efforts to optimize the quality of life of cancer survivors, thereby maximizing the number of uncomplicated cancer cures.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
1P20GM109005-01A1
Application #
8811544
Study Section
Special Emphasis Panel (ZGM1-TWD-A (1C))
Program Officer
Liu, Yanping
Project Start
2015-06-24
Project End
2020-03-31
Budget Start
2015-06-24
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$2,116,256
Indirect Cost
$695,950
Name
University of Arkansas for Medical Sciences
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Pathak, Rupak; Koturbash, Igor; Hauer-Jensen, Martin (2017) Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice. J Vis Exp :
Chang, Jianhui; Wang, Yingying; Pathak, Rupak et al. (2017) Whole body proton irradiation causes acute damage to bone marrow hematopoietic progenitor and stem cells in mice. Int J Radiat Biol 93:1312-1320
Miousse, Isabelle R; Pathak, Rupak; Garg, Sarita et al. (2017) Short-term dietary methionine supplementation affects one-carbon metabolism and DNA methylation in the mouse gut and leads to altered microbiome profiles, barrier function, gene expression and histomorphology. Genes Nutr 12:22
Byrum, Stephanie D; Burdine, Marie S; Orr, Lisa et al. (2017) Time- and radiation-dose dependent changes in the plasma proteome after total body irradiation of non-human primates: Implications for biomarker selection. PLoS One 12:e0174771
Harrill, Alison H; Lin, Haixia; Tobacyk, Julia et al. (2017) Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury. Exp Biol Med (Maywood) :1535370217740854
Wang, Yingying; Chang, Jianhui; Li, Xin et al. (2017) Low doses of oxygen ion irradiation cause long-term damage to bone marrow hematopoietic progenitor and stem cells in mice. PLoS One 12:e0189466
Chang, Jianhui; Feng, Wei; Wang, Yingying et al. (2017) 28Si total body irradiation injures bone marrow hematopoietic stem cells via induction of cellular apoptosis. Life Sci Space Res (Amst) 13:39-44
Banerjee, Sudip; Melnyk, Stepan B; Krager, Kimberly J et al. (2017) Trifluoperazine inhibits acetaminophen-induced hepatotoxicity and hepatic reactive nitrogen formation in mice and in freshly isolated hepatocytes. Toxicol Rep 4:134-142
Miousse, Isabelle R; Chang, Jianhui; Shao, Lijian et al. (2017) Inter-Strain Differences in LINE-1 DNA Methylation in the Mouse Hematopoietic System in Response to Exposure to Ionizing Radiation. Int J Mol Sci 18:
Fil, Daniel; DeLoach, Abigail; Yadav, Shilpi et al. (2017) Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet 26:686-701

Showing the most recent 10 out of 56 publications